GSK receives FDA approval for dissolvable Lamictal

05/11/2009 | Forbes

GlaxoSmithKline obtained FDA clearance to launch a soluble formulation of Lamictal, a treatment for epilepsy and bipolar disorder. Lamictal ODT is expected to be on the market by July in doses of 25, 50, 100 and 200 milligrams, GSK said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
Winston-Salem, NC